Chemotherapy for Biliary Tract Cancer in 2021.
biliary tract cancer
chemotherapy
cholangiocarcinoma
cytotoxic agents
genetic testing
immunotherapy
molecular targeted agents
precision medicine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Jul 2021
14 Jul 2021
Historique:
received:
18
06
2021
revised:
12
07
2021
accepted:
13
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Biliary tract cancer refers to a group of malignancies including cholangiocarcinoma, gallbladder cancer, and ampullary cancer. While surgical resection is considered the only curative treatment, postoperative recurrence can sometimes occur. Adjuvant chemotherapy is used to prolong prognosis in some cases. Many unresectable cases are also treated with chemotherapy. Therefore, systemic chemotherapy is widely introduced for the treatment of biliary tract cancer. Evidence on chemotherapy for biliary tract cancer is recently on the increase. Combination chemotherapy with gemcitabine and cisplatin is currently the standard of care for first-line chemotherapy in advanced cases. Recently, FOLFOX also demonstrated efficacy as a second-line treatment. In addition, efficacies of isocitrate dehydrogenase inhibitors and fibroblast growth factor receptor inhibitors have been shown. In the adjuvant setting, capecitabine monotherapy has become the standard of care in Western countries. In addition to conventional cytotoxic agents, molecular-targeted agents and immunotherapy have been evaluated in multiple clinical trials. Genetic testing is used to check for genetic alterations and molecular-targeted agents and immunotherapy are introduced based on tumor characteristics. In this article, we review the latest evidence of chemotherapy for biliary tract cancer.
Identifiants
pubmed: 34300274
pii: jcm10143108
doi: 10.3390/jcm10143108
pmc: PMC8305063
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Ann Oncol. 2019 May 1;30(5):788-795
pubmed: 30785198
JAMA. 2012 Jul 11;308(2):147-56
pubmed: 22782416
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Jpn J Clin Oncol. 2018 Apr 1;48(4):392-395
pubmed: 29462482
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Cancer Med. 2021 Mar;10(6):2088-2099
pubmed: 33635605
Am J Clin Oncol. 2021 Mar 1;44(3):93-98
pubmed: 33350678
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Br J Surg. 2018 Feb;105(3):192-202
pubmed: 29405274
Cancer. 2019 Dec 15;125(24):4426-4434
pubmed: 31454426
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Br J Cancer. 2018 Aug;119(3):291-295
pubmed: 29955136
Lancet Oncol. 2020 Jan;21(1):e29-e41
pubmed: 31908303
Cancer. 2015 Sep 15;121(18):3290-7
pubmed: 26052689
Eur J Cancer. 2018 Mar;92:11-19
pubmed: 29413685
J Hepatobiliary Pancreat Sci. 2016 Mar;23(3):149-57
pubmed: 26699688
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Cancer Chemother Pharmacol. 2010 May;65(6):1101-7
pubmed: 19707761
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461347
Cancer Sci. 2013 Sep;104(9):1211-6
pubmed: 23763511
Eur J Cancer. 2020 May;130:219-227
pubmed: 32234665
Eur J Cancer. 2014 Dec;50(18):3125-35
pubmed: 25446376
JAMA Oncol. 2020 Sep 1;6(9):1405-1409
pubmed: 32729929
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
J Clin Oncol. 2019 Apr 20;37(12):1015-1027
pubmed: 30856044
Lancet Oncol. 2015 Aug;16(8):967-78
pubmed: 26179201
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Future Oncol. 2020 Jun;16(16):1069-1081
pubmed: 32374623
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2010 Oct 20;28(30):4581-6
pubmed: 20855823
Cancer Res Treat. 2015 Apr;47(2):259-65
pubmed: 25648099
Invest New Drugs. 2018 Dec;36(6):1093-1102
pubmed: 30324343
Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34
pubmed: 20811895
Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9
pubmed: 23355041
Eur J Cancer. 2019 Dec;123:162-170
pubmed: 31707181
JAMA Oncol. 2021 Mar 01;7(3):436-439
pubmed: 33270098
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32487569
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Acta Oncol. 2012 Sep;51(7):860-6
pubmed: 22559158
Anticancer Res. 2017 Sep;37(9):5193-5197
pubmed: 28870954
Br J Cancer. 2010 Aug 10;103(4):469-74
pubmed: 20628385
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
Invest New Drugs. 2012 Apr;30(2):708-13
pubmed: 20924641
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Cancer Chemother Pharmacol. 2013 May;71(5):1141-6
pubmed: 23525694
Ann Oncol. 2015 Mar;26(3):542-7
pubmed: 25538178
JAMA Oncol. 2019 Jun 01;5(6):824-830
pubmed: 30998813
Br J Cancer. 2009 Aug 18;101(4):621-7
pubmed: 19672264
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Ann Oncol. 2020 Sep;31(9):1169-1177
pubmed: 32464280
Ann Oncol. 1996 Aug;7(6):593-600
pubmed: 8879373
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Cancer Chemother Pharmacol. 2015 Feb;75(2):293-300
pubmed: 25477010
Eur J Cancer. 2013 Jan;49(2):329-35
pubmed: 22947649
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
Lancet Oncol. 2014 Jul;15(8):819-28
pubmed: 24852116
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
BMC Cancer. 2020 Feb 14;20(1):122
pubmed: 32059704
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110
pubmed: 35900311
Lancet Oncol. 2012 Feb;13(2):181-8
pubmed: 22192731
Eur J Cancer. 2013 Apr;49(6):1511
pubmed: 23265701
Ann Oncol. 2019 Dec 1;30(12):1950-1958
pubmed: 31566666
Ann Oncol. 2015 May;26(5):943-949
pubmed: 25632066
J Clin Oncol. 2019 Mar 10;37(8):658-667
pubmed: 30707660
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Cancer Sci. 2021 Mar;112(3):1105-1113
pubmed: 33403729
Cancer. 2016 Feb 15;122(4):574-81
pubmed: 26540314
Cancers (Basel). 2020 Jul 20;12(7):
pubmed: 32698410
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):885-893
pubmed: 32359831
J Gastroenterol. 2021 Mar;56(3):250-260
pubmed: 33106918
Br J Cancer. 2007 Mar 26;96(6):896-902
pubmed: 17325704
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Cancer. 2002 Oct 15;95(8):1685-95
pubmed: 12365016
Cancer Chemother Pharmacol. 2016 Jan;77(1):109-14
pubmed: 26659366
BMC Cancer. 2015 Jul 31;15:564
pubmed: 26228433
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
Ann Oncol. 2020 Jul;31(7):861-872
pubmed: 32272210
Eur J Cancer. 2021 Jan;143:55-63
pubmed: 33279854
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33172881
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808